protein extracts 406 Search Results


il 1b r d system  (R&D Systems)
93
R&D Systems il 1b r d system
Il 1b R D System, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 1b r d system/product/R&D Systems
Average 93 stars, based on 1 article reviews
il 1b r d system - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
recombinant mouse il 9 r d systems  (R&D Systems)
96
R&D Systems recombinant mouse il 9 r d systems
Recombinant Mouse Il 9 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse il 9 r d systems/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant mouse il 9 r d systems - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
anti phospho eif4b ser406  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc anti phospho eif4b ser406
IBL-301 alters NSCLC cell line protein expression and signaling pathways. ( A ) H1975 cells were treated with DMSO vehicle control, 250 nM PI3K/mTOR inhibitor BEZ235 or 250 nM PI3K/mTOR/PIM inhibitor IBL-301 for 24 h, protein was extracted and assayed using a PathScan ® intracellular signaling array ( n = 1). The top altered pathways by IBL-301 were Akt (Thr308 and Ser473), AMPKa, BAD, GSK-3B and SAPK/JNK while the top altered pathways by BEZ235 were Akt (Ser473), S6, mTOR and p53. ( B ) H1975 cells were treated with DMSO vehicle control (UT), 250 nM of PI3K inhibitor GDC0941, PI3K/mTOR inhibitor GDC0980 or PI3K/mTOR/PIM inhibitor IBL-301 for 2, 6 and 24 h, followed by protein extraction and Western blotting for PIM1, p-4EBP1 (Thr37/46), <t>p-eIF4B</t> <t>(Ser406)</t> and endogenous control αβ-tubulin. After an initial increase in PIM-1S across all treatments, expression decreased at 24 h. Across all time points, IBL-301 was most effective at inhibiting PIM-1L expression and phosphorylation of 4EBP1 (Thr37/46) and eIF4B (Ser406). ( C ) NSCLC cell lines H1838, H1975 and Calu-6 were treated with 250 nM and 500 nM IBL-301 for 6 and 24 h followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Both drug concentrations decreased c-Myc expression across the time points in the H1838 and the H1975 cells, while only 500 nM IBL-301 decreased c-Myc in Calu-6 at 6 and 24 h. ( D ) H1838 were treated with DMSO control (UT), 250 nM BEZ235 or 250 nM IBL-301 for 6 and 24 h, followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Using 250 nM IBL-301 reduced c-Myc levels at both time points while in contrast 250 nM BEZ235 had no observed effect on c-Myc across the time points tested. Original Western blots for B–D in .
Anti Phospho Eif4b Ser406, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho eif4b ser406/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
anti phospho eif4b ser406 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
cas  (Bio-Rad)
93
Bio-Rad cas
IBL-301 alters NSCLC cell line protein expression and signaling pathways. ( A ) H1975 cells were treated with DMSO vehicle control, 250 nM PI3K/mTOR inhibitor BEZ235 or 250 nM PI3K/mTOR/PIM inhibitor IBL-301 for 24 h, protein was extracted and assayed using a PathScan ® intracellular signaling array ( n = 1). The top altered pathways by IBL-301 were Akt (Thr308 and Ser473), AMPKa, BAD, GSK-3B and SAPK/JNK while the top altered pathways by BEZ235 were Akt (Ser473), S6, mTOR and p53. ( B ) H1975 cells were treated with DMSO vehicle control (UT), 250 nM of PI3K inhibitor GDC0941, PI3K/mTOR inhibitor GDC0980 or PI3K/mTOR/PIM inhibitor IBL-301 for 2, 6 and 24 h, followed by protein extraction and Western blotting for PIM1, p-4EBP1 (Thr37/46), <t>p-eIF4B</t> <t>(Ser406)</t> and endogenous control αβ-tubulin. After an initial increase in PIM-1S across all treatments, expression decreased at 24 h. Across all time points, IBL-301 was most effective at inhibiting PIM-1L expression and phosphorylation of 4EBP1 (Thr37/46) and eIF4B (Ser406). ( C ) NSCLC cell lines H1838, H1975 and Calu-6 were treated with 250 nM and 500 nM IBL-301 for 6 and 24 h followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Both drug concentrations decreased c-Myc expression across the time points in the H1838 and the H1975 cells, while only 500 nM IBL-301 decreased c-Myc in Calu-6 at 6 and 24 h. ( D ) H1838 were treated with DMSO control (UT), 250 nM BEZ235 or 250 nM IBL-301 for 6 and 24 h, followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Using 250 nM IBL-301 reduced c-Myc levels at both time points while in contrast 250 nM BEZ235 had no observed effect on c-Myc across the time points tested. Original Western blots for B–D in .
Cas, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cas/product/Bio-Rad
Average 93 stars, based on 1 article reviews
cas - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
both238 il 6  (R&D Systems)
96
R&D Systems both238 il 6
IBL-301 alters NSCLC cell line protein expression and signaling pathways. ( A ) H1975 cells were treated with DMSO vehicle control, 250 nM PI3K/mTOR inhibitor BEZ235 or 250 nM PI3K/mTOR/PIM inhibitor IBL-301 for 24 h, protein was extracted and assayed using a PathScan ® intracellular signaling array ( n = 1). The top altered pathways by IBL-301 were Akt (Thr308 and Ser473), AMPKa, BAD, GSK-3B and SAPK/JNK while the top altered pathways by BEZ235 were Akt (Ser473), S6, mTOR and p53. ( B ) H1975 cells were treated with DMSO vehicle control (UT), 250 nM of PI3K inhibitor GDC0941, PI3K/mTOR inhibitor GDC0980 or PI3K/mTOR/PIM inhibitor IBL-301 for 2, 6 and 24 h, followed by protein extraction and Western blotting for PIM1, p-4EBP1 (Thr37/46), <t>p-eIF4B</t> <t>(Ser406)</t> and endogenous control αβ-tubulin. After an initial increase in PIM-1S across all treatments, expression decreased at 24 h. Across all time points, IBL-301 was most effective at inhibiting PIM-1L expression and phosphorylation of 4EBP1 (Thr37/46) and eIF4B (Ser406). ( C ) NSCLC cell lines H1838, H1975 and Calu-6 were treated with 250 nM and 500 nM IBL-301 for 6 and 24 h followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Both drug concentrations decreased c-Myc expression across the time points in the H1838 and the H1975 cells, while only 500 nM IBL-301 decreased c-Myc in Calu-6 at 6 and 24 h. ( D ) H1838 were treated with DMSO control (UT), 250 nM BEZ235 or 250 nM IBL-301 for 6 and 24 h, followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Using 250 nM IBL-301 reduced c-Myc levels at both time points while in contrast 250 nM BEZ235 had no observed effect on c-Myc across the time points tested. Original Western blots for B–D in .
Both238 Il 6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/both238 il 6/product/R&D Systems
Average 96 stars, based on 1 article reviews
both238 il 6 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
6x his tag antibody biotin conjugated  (Rockland Immunochemicals)
N/A
Anti 6X HIS EPITOPE TAG MOUSE Monoclonal Antibody Biotin Conjugated 200 306 382
   Buy from Supplier
mammalian cell protein extract  (Genesee Scientific)
N/A
Prometheus Protein Biology Products 18 406 Mammalian Cell Protein Extraction Buffer Total Protein Extraction 250 mL UnitTotal Protein Extraction
   Buy from Supplier
e.coli / yeast protein extraction buffer  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier
ha epitope tag antibody biotin conjugated  (Rockland Immunochemicals)
N/A
Anti HA EPITOPE TAG RABBIT Antibody Biotin Conjugated 600 406 384
   Buy from Supplier
maltose binding protein mbp epitope tag antibody biotin conjugated  (Rockland Immunochemicals)
N/A
Anti MALTOSE BINDING PROTEIN MBP EPITOPE TAG RABBIT Antibody Biotin Conjugated 200 406 385
   Buy from Supplier

Image Search Results


IBL-301 alters NSCLC cell line protein expression and signaling pathways. ( A ) H1975 cells were treated with DMSO vehicle control, 250 nM PI3K/mTOR inhibitor BEZ235 or 250 nM PI3K/mTOR/PIM inhibitor IBL-301 for 24 h, protein was extracted and assayed using a PathScan ® intracellular signaling array ( n = 1). The top altered pathways by IBL-301 were Akt (Thr308 and Ser473), AMPKa, BAD, GSK-3B and SAPK/JNK while the top altered pathways by BEZ235 were Akt (Ser473), S6, mTOR and p53. ( B ) H1975 cells were treated with DMSO vehicle control (UT), 250 nM of PI3K inhibitor GDC0941, PI3K/mTOR inhibitor GDC0980 or PI3K/mTOR/PIM inhibitor IBL-301 for 2, 6 and 24 h, followed by protein extraction and Western blotting for PIM1, p-4EBP1 (Thr37/46), p-eIF4B (Ser406) and endogenous control αβ-tubulin. After an initial increase in PIM-1S across all treatments, expression decreased at 24 h. Across all time points, IBL-301 was most effective at inhibiting PIM-1L expression and phosphorylation of 4EBP1 (Thr37/46) and eIF4B (Ser406). ( C ) NSCLC cell lines H1838, H1975 and Calu-6 were treated with 250 nM and 500 nM IBL-301 for 6 and 24 h followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Both drug concentrations decreased c-Myc expression across the time points in the H1838 and the H1975 cells, while only 500 nM IBL-301 decreased c-Myc in Calu-6 at 6 and 24 h. ( D ) H1838 were treated with DMSO control (UT), 250 nM BEZ235 or 250 nM IBL-301 for 6 and 24 h, followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Using 250 nM IBL-301 reduced c-Myc levels at both time points while in contrast 250 nM BEZ235 had no observed effect on c-Myc across the time points tested. Original Western blots for B–D in .

Journal: Cancers

Article Title: Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC

doi: 10.3390/cancers13092139

Figure Lengend Snippet: IBL-301 alters NSCLC cell line protein expression and signaling pathways. ( A ) H1975 cells were treated with DMSO vehicle control, 250 nM PI3K/mTOR inhibitor BEZ235 or 250 nM PI3K/mTOR/PIM inhibitor IBL-301 for 24 h, protein was extracted and assayed using a PathScan ® intracellular signaling array ( n = 1). The top altered pathways by IBL-301 were Akt (Thr308 and Ser473), AMPKa, BAD, GSK-3B and SAPK/JNK while the top altered pathways by BEZ235 were Akt (Ser473), S6, mTOR and p53. ( B ) H1975 cells were treated with DMSO vehicle control (UT), 250 nM of PI3K inhibitor GDC0941, PI3K/mTOR inhibitor GDC0980 or PI3K/mTOR/PIM inhibitor IBL-301 for 2, 6 and 24 h, followed by protein extraction and Western blotting for PIM1, p-4EBP1 (Thr37/46), p-eIF4B (Ser406) and endogenous control αβ-tubulin. After an initial increase in PIM-1S across all treatments, expression decreased at 24 h. Across all time points, IBL-301 was most effective at inhibiting PIM-1L expression and phosphorylation of 4EBP1 (Thr37/46) and eIF4B (Ser406). ( C ) NSCLC cell lines H1838, H1975 and Calu-6 were treated with 250 nM and 500 nM IBL-301 for 6 and 24 h followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Both drug concentrations decreased c-Myc expression across the time points in the H1838 and the H1975 cells, while only 500 nM IBL-301 decreased c-Myc in Calu-6 at 6 and 24 h. ( D ) H1838 were treated with DMSO control (UT), 250 nM BEZ235 or 250 nM IBL-301 for 6 and 24 h, followed by protein extraction and Western blotting for c-Myc and αβ-tubulin. Using 250 nM IBL-301 reduced c-Myc levels at both time points while in contrast 250 nM BEZ235 had no observed effect on c-Myc across the time points tested. Original Western blots for B–D in .

Article Snippet: Anti-PIM-1 (Cat# 3247) or anti-PIM-1 (Cat#2907), anti-PIM-2 (Cat# 4730), anti-PIM-3 (Cat# 4165), anti-c-Myc (Cat# 9402), anti-p21 (Cat# 2947), anti-mTOR (Cat# 2983) and anti-phospho-mTOR (Ser2448) (Cat# 2971), anti-pAKT (Ser473) (Cat# 4058), anti-4EBP1 (Cat# 9644), anti-phospho-S6 (Ser240/244) (Cat# 2215), anti-phospho-4EBP1 (Thr37/46) (Cat# 2855), anti-phospho-eIF4B (Ser406) (Cat# 5399) and anti-αβ-tubulin (Cat #2148) rabbit primary antibodies were purchased from Cell Signaling Technology and diluted as per manufacturer’s protocol.

Techniques: Expressing, Protein-Protein interactions, Control, Protein Extraction, Western Blot, Phospho-proteomics

Protein evaluation of identified genes associated with PI3K/mTOR inhibitor resistance in the H1975GR cells. ( A ). Representative Western blot images showing significant upregulation of PIM1L ( p < 0.01), PIM2 ( p = 0.054), PIM3 ( p < 0.05), c-Myc ( p < 0.05), and downregulation of p21 (CIP1/WAF1) ( p < 0.05) in H1975GR compared to age matched parent H1975P cells. ( B ) Representative Western blot images showing alterations in PI3K/mTOR signaling between H1975P and H1975GR. H1975GR show upregulated p-mTOR ( p < 0.01), unaltered mTOR and upregulated p-AKT ( p < 0.01). H1975GR show hyperphosphorylated S6 ( p < 0.05), in contrast to decreased total 4EBP1 ( p = 0.0701) and hypo phosphorylated 4EBP1 (Thr37/46) ( p < 0.01). ( C ) p-4EBP1 (Thr37/46) showed a similar downregulation across all GDC-0980 resistant NSCLC cell line models and p-eIF4B (Ser406) was downregulated in H460GR and A549GR cells compared to the corresponding parent cell lines. ( D ) Conditioned media from H1975GR and H1975P cells were assayed using a magnetic bead based immunoassay (MILLIPLEX MAP), H1975GR secreted higher MCP-1 and TNF-α (both p < 0.05), and decreased RANTES ( p < 0.001) compared to H1975P. * p < 0.05, *** p < 0.001, paired student t -test, n ≥ 3. Original Western blots for A–C in .

Journal: Cancers

Article Title: Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC

doi: 10.3390/cancers13092139

Figure Lengend Snippet: Protein evaluation of identified genes associated with PI3K/mTOR inhibitor resistance in the H1975GR cells. ( A ). Representative Western blot images showing significant upregulation of PIM1L ( p < 0.01), PIM2 ( p = 0.054), PIM3 ( p < 0.05), c-Myc ( p < 0.05), and downregulation of p21 (CIP1/WAF1) ( p < 0.05) in H1975GR compared to age matched parent H1975P cells. ( B ) Representative Western blot images showing alterations in PI3K/mTOR signaling between H1975P and H1975GR. H1975GR show upregulated p-mTOR ( p < 0.01), unaltered mTOR and upregulated p-AKT ( p < 0.01). H1975GR show hyperphosphorylated S6 ( p < 0.05), in contrast to decreased total 4EBP1 ( p = 0.0701) and hypo phosphorylated 4EBP1 (Thr37/46) ( p < 0.01). ( C ) p-4EBP1 (Thr37/46) showed a similar downregulation across all GDC-0980 resistant NSCLC cell line models and p-eIF4B (Ser406) was downregulated in H460GR and A549GR cells compared to the corresponding parent cell lines. ( D ) Conditioned media from H1975GR and H1975P cells were assayed using a magnetic bead based immunoassay (MILLIPLEX MAP), H1975GR secreted higher MCP-1 and TNF-α (both p < 0.05), and decreased RANTES ( p < 0.001) compared to H1975P. * p < 0.05, *** p < 0.001, paired student t -test, n ≥ 3. Original Western blots for A–C in .

Article Snippet: Anti-PIM-1 (Cat# 3247) or anti-PIM-1 (Cat#2907), anti-PIM-2 (Cat# 4730), anti-PIM-3 (Cat# 4165), anti-c-Myc (Cat# 9402), anti-p21 (Cat# 2947), anti-mTOR (Cat# 2983) and anti-phospho-mTOR (Ser2448) (Cat# 2971), anti-pAKT (Ser473) (Cat# 4058), anti-4EBP1 (Cat# 9644), anti-phospho-S6 (Ser240/244) (Cat# 2215), anti-phospho-4EBP1 (Thr37/46) (Cat# 2855), anti-phospho-eIF4B (Ser406) (Cat# 5399) and anti-αβ-tubulin (Cat #2148) rabbit primary antibodies were purchased from Cell Signaling Technology and diluted as per manufacturer’s protocol.

Techniques: Western Blot, Bead-based Assay